Q-Glyntiva
One dose. Twice daily. Five pathways. A mitochondrial-targeted metabolic blend.
Two endpoints, one consistent curve
Q-Glyntiva vs placebo across a 26-week, double-blind, placebo-controlled trial (n=120).
HbA1c vs Placebo
Fasting Glucose vs Placebo
Curves are stylized redraws of the sales sheet's trial charts, preserving the same shape and literal endpoint values — not pixel-traced source data.
Five overlapping T2DM drivers
One pathway is never enough.
One blend, five pathways
Beyond Glucose — Metabolic & Cardiometabolic Endpoints (Month 6)
Why formulators are switching
QuanticSphere™ PQNS delivery, engineered in two layers
PQNS — Phytosome Quantum Nano Sphere
Phytochemicals in a biomimetic phospholipid shell that fuses with cell membranes on contact — supporting higher absorption than standard, unencapsulated extracts.
Patent pending · 202521095813Programmable Release
The release profile is engineered into the PQNS carrier, not the finished dosage form — so it holds in either tablet or capsule.
Targeted Intestinal ReleaseBuilt for formulators
Common questions about Q-Glyntiva
Straight answers for formulators, distributors and brand buyers.
Q-Glyntiva is a mitochondrial-targeted metabolic blend designed to help reduce blood glucose, engineered from the cell up. One fixed-dose blend addresses five overlapping T2DM drivers, delivered by QuanticSphere™ PQNS.
Standard glucose-support products typically target a single pathway. Q-Glyntiva combines five pathways — mitochondrial support, antioxidant defense, fat metabolism, metabolic signaling and polyphenol support — in one fixed-dose, twice-daily blend delivered via QuanticSphere™ PQNS.
PQNS (Phytosome Quantum Nano Sphere) is a biomimetic phospholipid shell that fuses with cell membranes on contact, designed to support higher absorption than standard, unencapsulated extracts. The release profile is engineered into the PQNS carrier itself — not the finished dosage form — so it holds in either tablet or capsule (Targeted Intestinal Release). This delivery system has a patent pending (No. 202521095813).
In a 26-week, double-blind, placebo-controlled trial (n=120), Q-Glyntiva reduced HbA1c from 8.1% to 6.0% (−1.6 points vs placebo, p<0.0001) and fasting glucose from 315 to 101 mg/dL (placebo −5.1%, p<0.0001). 78% of participants reached HbA1c ≥ 6.5% and 91% reached fasting blood sugar ≤ 130 mg/dL, with 0 significant hypoglycemia and 0 serious adverse events. At month 6, the trial also recorded improvements beyond glucose: −57% HOMA-IR, +85.7% adiponectin, −57.8% postprandial glucose, −18.8% LDL-C, −27.3% triglycerides and −56.3% hsCRP.
Request samples, MOQ and the full clinical dossier at info@integriacare.com.
Request samples, MOQ & the full clinical dossier
Talk to our team about volumes, blend specifications and technical documentation for your finished product.